Key result
Chemotherapy in patients with solid tumors was associated with an 89.5% incidence of anemia, with grade 2+ anemia ranging from 26.3% in colorectal cancer to 59.2% in ovarian cancer.
Why the study?
What is the incidence and severity of anemia in patients with solid tumors receiving chemotherapy?
Cohort (n=4,426)
What is the incidence and severity of anemia in patients with solid tumors receiving chemotherapy?
Moderate-to-severe anemia remains highly prevalent in patients with solid tumors undergoing chemotherapy, particularly in those with distant metastasis or receiving specific regimens.
No takes yet. Share an insight, caveat, or question.
Supports heightened anemia surveillance during chemotherapy for solid tumors; extends incidence estimates by cancer type in a large cohort.
Xu et al. (2016) conducted a cohort in Solid tumors (breast, lung, colon/rectum, stomach, ovary) (n=4,426). Chemotherapy was evaluated on Incidence of anemia during the course of chemotherapy. Chemotherapy in patients with solid tumors was associated with an 89.5% incidence of anemia, with grade 2+ anemia ranging from 26.3% in colorectal cancer to 59.2% in ovarian cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: